BioMimetic kick-starts pivotal EU trial for GEM OS1 bone graft substitute
This article was originally published in Clinica
Executive Summary
BioMimetic Therapeutics has begun enrolling patients into a pivotal European study to assess its GEM OS1 bone graft as a substitute for autograft in foot and ankle fusion procedures.